TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzheimer's treatment Leqembi and the company's limited candidate portfolio concentrated in the dementia drug field.
At an Eisai financial results briefing on Feb. 7, analysts focused on the sales outlook for Leqembi. "The market wants to know when Leqemi sales will reach $1 billion and how soon will the company known when it will reach that target," one analyst asked.
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)